Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure

被引:33
作者
Bostom, Andrew [1 ]
Steubl, Dominik [2 ]
Garimella, Pranav S. [3 ]
Franceschini, Nora [4 ]
Roberts, Mary B. [1 ]
Pasch, Andreas [5 ]
Ix, Joachim H. [3 ]
Tuttle, Katherine R. [6 ]
Ivanova, Anastasia [4 ]
Shireman, Theresa [7 ]
Kim, S. Joseph [8 ,9 ]
Gohh, Reginald [10 ]
Weiner, Daniel E. [11 ]
Levey, Andrew S. [11 ]
Hsu, Chi-yuan [12 ]
Kusek, John W. [13 ]
Eaton, Charles B. [14 ,15 ]
机构
[1] Mem Hosp Rhode Isl, Ctr Primary Care & Prevent, 111 Brewster St, Pawtucket, RI 02860 USA
[2] Tech Univ, Klinikum Rechts Isar, Munich, Germany
[3] Univ Calif San Diego, Dept Med, Div Nephrol Hypertens, San Diego, CA 92103 USA
[4] Univ N Carolina, Gillings Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA
[5] Univ Bern, Bern, Switzerland
[6] Univ Washington, Providence Med Res Ctr, Spokane, WA USA
[7] Brown Univ, Ctr Gerontol & Healthcare Res, Providence, RI 02912 USA
[8] Toronto Gen Hosp, Div Nephrol, Toronto, ON, Canada
[9] Toronto Gen Hosp, Kidney Transplant Program, Toronto, ON, Canada
[10] Rhode Isl Hosp, Dept Med, Div Hypertens & Kidney Dis, Providence, RI 02903 USA
[11] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA
[12] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA
[13] NIDDK, NIH, Bethesda, MD 20892 USA
[14] Brown Univ, Warren Alpert Med Sch, Dept Family Med, Providence, RI 02912 USA
[15] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA
基金
美国国家卫生研究院;
关键词
Serum uromodulin; Kidney transplantation; Kidney allograft failure; TAMM-HORSFALL PROTEIN; VASCULAR OUTCOME REDUCTION; CARDIOVASCULAR-DISEASE; TRANSPLANT RECIPIENTS; URINARY UROMODULIN; FOLIC-ACID; MORTALITY; RISK; HEALTH; GLYCOPROTEIN;
D O I
10.1159/000489095
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Uromodulin is a kidney-derived glycoprotein and putative tubular function index. Lower serum uromodulin was recently associated with increased risk for kidney allograft failure in a preliminary, longitudinal single-center -European study involving 91 kidney transplant recipients (KTRs). Methods: The Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial is a completed, large, multiethnic controlled clinical trial cohort, which studied chronic, stable KTRs. We conducted a case cohort analysis using a randomly selected subset of patients (random subcohort, n = 433), and all individuals who developed kidney allograft failure (cases, n = 226) during follow-up. Serum uromodulin was determined in this total of n = 613 FAVORIT trial participants at randomization. Death-censored kidney allograft failure was the study outcome. Results: The 226 kidney allograft failures occurred during a median surveillance of 3.2 years. Unadjusted, weighted Cox proportional hazards modeling revealed that lower serum uromodulin, tertile 1 vs. tertile 3, was associated with a threefold greater risk for kidney allograft failure (hazards ratio [HR], 95% CI 3.20 [2.05-5.01]). This association was attenuated but persisted at two-fold greater risk for allograft failure, after adjustment for age, sex, smoking, allograft type and vintage, prevalent diabetes mellitus and cardiovascular disease (CVD), total/high-density lipoprotein cholesterol ratio, systolic blood pressure, estimated glomerular filtration rate, and natural log urinary albumin/creatinine: HR 2.00, 95% CI (1.06-3.77). Conclusions: Lower serum uromodulin, a possible indicator of less well-preserved renal tubular function, remained associated with greater risk for kidney allograft failure, after adjustment for major, established clinical kidney allograft failure and CVD risk factors, in a large, multiethnic cohort of long-term, stable KTRs. (C) 2018 S. Karger AG, Basel
引用
收藏
页码:275 / 282
页数:8
相关论文
共 42 条
  • [1] [Anonymous], 2013, FAVORIT DATA DICT AN
  • [2] AVIS PJG, 1985, LANCET, V2, P154
  • [3] Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial
    Bansal, Nisha
    Carpenter, Myra A.
    Weiner, Daniel E.
    Levey, Andrew S.
    Pfeffer, Marc
    Kusek, John W.
    Cai, Jianwen
    Hunsicker, Lawrence G.
    Park, Meyeon
    Bennett, Michael
    Liu, Kathleen D.
    Hsu, Chi-yuan
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (07): : 2109 - 2121
  • [4] ROBUST VARIANCE-ESTIMATION FOR THE CASE-COHORT DESIGN
    BARLOW, WE
    [J]. BIOMETRICS, 1994, 50 (04) : 1064 - 1072
  • [5] Analysis of case-cohort designs
    Barlow, WE
    Ichikawa, L
    Rosner, D
    Izumi, S
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (12) : 1165 - 1172
  • [6] Bostom AG, 2017, TRANSPLANT DIRECT, V3, DOI 10.1097/TXD.0000000000000737
  • [7] Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial
    Bostom, Andrew G.
    Carpenter, Myra A.
    Kusek, John W.
    Levey, Andrew S.
    Hunsicker, Lawrence
    Pfeffer, Marc A.
    Selhub, Jacob
    Jacques, Paul F.
    Cole, Edward
    Gravens-Mueller, Lisa
    House, Andrew A.
    Kew, Clifton
    McKenney, Joyce L.
    Pacheco-Silva, Alvaro
    Pesavento, Todd
    Pirsch, John
    Smith, Stephen
    Solomon, Scott
    Weir, Matthew
    [J]. CIRCULATION, 2011, 123 (16) : 1763 - 1770
  • [8] Baseline Characteristics of Participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
    Bostom, Andrew G.
    Carpenter, Myra A.
    Hunsicker, Lawrence
    Jacques, Paul F.
    Kusek, John W.
    Levey, Andrew S.
    McKenney, Joyce L.
    Mercier, Renee Y.
    Pfeffer, Marc A.
    Selhub, Jacob
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (01) : 121 - 128
  • [9] BP, Cardiovascular Disease, and Death in the Folic Acid for Vascular Outcome Reduction in Transplantation Trial
    Carpenter, Myra A.
    John, Alin
    Weir, Matthew R.
    Smith, Stephen R.
    Hunsicker, Lawrence
    Kasiske, Bertram L.
    Kusek, John W.
    Bostom, Andrew
    Ivanova, Anastasia
    Levey, Andrew S.
    Solomon, Scott
    Pesavento, Todd
    Weiner, Daniel E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 25 (07): : 1554 - 1562
  • [10] DAWNAY ABS, 1981, CLIN NEPHROL, V15, P5